玻璃体腔注射雷珠单抗治疗湿性年龄相关性黄斑变性的临床研究

Clinical study of vitreous cavity injection of Lucentis in the treatment of wet type age-related macular degeneration

目的评价玻璃体腔注射雷珠单抗治疗湿性年龄相关性黄斑变性的临床疗效。方法 35例湿性年龄相关性黄斑变性患者,均采取玻璃体腔注射雷珠单抗治疗,评价治疗效果。结果 35例患者经治疗,显效28例(80.00%)、有效6例(17.14%)、无效1例(2.86%),总有效率为97.14%。治疗3个月后,患者的最佳矫正视力(BCVA)为(0.492±0.034)高于治疗前(0.184±0.020)、黄斑中心凹厚度(CFT)为(228.390±82.930)mm低于治疗前(462.560±74.320)mm,差异均具有统计学意义(P<0.05)。结论玻璃体腔注射雷珠单抗治疗湿性年龄相关性黄斑变性疗效显著,值得推广及应用。

Objective To evaluate the clinical curative effect of vitreous cavity injection of Lucentis in the treatment of wet type age-related macular degeneration. Methods A total of 35 patients with wet type agerelated macular degeneration all received vitreous cavity injection of Lucentis for treatment, and their therapeutic effect was evaluated. Results Among 35 patients, after treatment, there were 28 excellent cases（80.00%）, 6 effective cases（17.14%） and 1 ineffective case（2.86%）, with total effective rate as 97.14%. After 3 months of treatment, patients had higher best corrected visual acuity（BCVA） as（0.492±0.034） than（0.184±0.020） before treatment, and lower central foveal thickness（CFT） as（228.390±82.930） mm than（462.560±74.320） mm before treatment. Their difference had statistical significance（P〈0.05）. Conclusion Vitreous cavity injection of Lucentis shows significant curative effect in treating wet type age-related macular degeneration, and it is worthy of promotion and application.